Thomas Blevins, M.D., Texas Diabetes and Endocrinology,6500 North Mopac Expressway, Building 3, Suite 200, Austin,Texas 78731. E-mail: tblevins@texasdiabetes.com. Portions of these data were previously presented at the Amer- ican Diabetes Association 70th Scientific Sessions, Orlando, FL,2010, and at the 46th Annual Meeting of the European Associ-ation for the Study of Diabetes, Stockholm, Sweden, 2010. Disclosure Summary: T.B. and J.P. have received research grants from Amylin Pharmaceuticals, Inc. and serve as advisersand speaker’s bureau members for Amylin Pharmaceuticals, Inc.T.B. has served as an adviser and speaker’s bureau member forEli Lilly & Co. J.M., P.Y., K.T., C.S., and L.P. are employees andstockholders of Amylin Pharmaceuticals, Inc. M.T. is an em-ployee and stockholder of Eli Lilly & Co. References 1.U.K. Prospective Diabetes Study (UKPDS) Group 1998 Intensive